Sentences with phrase «drug prices as»

A bit later, Trump detoured into an portion of the speech on the pharmaceutical industry, declaring the «injustice» of high U.S. drug prices as one of his «top priorities for the year.»

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.Chip Somodevilla / Getty Imageshide caption

Health and Human Services Secretary Alex Azar talked Friday about the administration's plans to lower drug prices as President Trump looked on in the White House Rose Garden.

This was due, in part, to reductions in the rate at which payments to certain providers are updated; slower growth in the use of Part A services, such as skilled nursing facility and home health services; and reductions in prescription drug prices as patents for several popular drugs expired.

Health insurers, which have pointed to skyrocketing drug prices as a source of premium hikes, welcomed the proposal.

However analysts point to a bounce in Teva's shares over the past four months and a slowing in the rate of decline of U.S. generic drug prices as bright spots.

Not exact matches

There are also forums dedicated to policy issues such as drug pricing and medical standards — last year, former Vice President Joe Biden announced a federal Genomic Data Commons to expedite cancer research during a keynote address.

Spending on new drugs for those diseases is expected to rise 7 % in 2018, and it's less due to price hikes as it is for the high prices associated with these specialty therapies.

Soliris's price can run as high as $ 700,000 a year, with the drug accounting for the bulk of Alexion's $ 3 billion in 2016 sales.

And, as Barrett and Langreth write, drug makers often raise those list prices «to make up some of the lost revenue» from rebating.

While we wait to see how much Newfoundland is able to extract, note that Ottawa offered two other similarly vague compensation deals to get CETA through: One on drug prices, tied to a lengthening of patent protection, and another to the dairy industry as protection against an increase in duty - free European cheese.

«We are reviewing the Committee's request and, as we have and continue to do with similar congressional inquiries, we look forward to having an open and honest dialogue about drug pricing.»

As a recent member of Valeant's board, I am committed to ensuring that this approach to drug pricing is never repeated at Valeant.»

On the surface, Papa seems to have gotten an extraordinarily generous deal to turn around the beleaguered drug company: Not only is his salary more than twice what it was when he was CEO of Perrigo (prgo), a company nearly three times as valuable as Valeant (vrx), it's also especially good considering Valeant's stock price has fallen nearly 67 % since he took over.

But before his arrest, he said he'd use KaloBios as a vehicle to nab another niche drug, this time for treatment of the parasitic infection Chagas disease, and dramatically increase its price to the $ 60,000 to $ 100,000 range after helping it win FDA approval (the drug is approved in other countries and is provided to patients in the U.S. on a special and selective basis).

Activist hedge fund investor and recent Valeant Pharmaceuticals (vrx) board appointee Bill Ackman on Wednesday slammed the company's steep drug price hikes in testimony before the U.S. Senate Special Committee on Aging, going so far as to say the cost bumps «contributed to healthcare inflation and called into question the company's commitment to the patients it serves.»

Martin Shkreli, unaffectionately known as the «pharma bro» — and infamous for his decision to hike the list price of Daraprim, a drug used by HIV / AIDS and cancer patients to combat infections, by more than 5,000 % in 2015 under his former company Turing Pharmaceuticals — was convicted on three criminal securities fraud and conspiracy charges by a Brooklyn jury on Friday.

He added that the media focuses on examples of individual drug price hikes, it has overlooked the fact that expense of drugs as a proportion of healthcare spending has remained «remarkably constant» over the years.

Valeant, as the story unfolded, bought existing medications from other drug makers, as well as whole companies - then relentlessly hiked the prices of the drugs it acquired.

As lawmakers and the public scrutinize dramatic price increases for other old drugs — most recently with the Mylan - owned EpiPen, which saw its cost go up by 500 % in the past nine years — the next flash point may be insulin, a drug both ubiquitous and complicated.

It is also under investigation by the U.S. Securities and Exchange Commission, U.S. Attorney's offices in Massachusetts and New York, as well as Congress, as part of their probes into price hikes for certain drugs.

However, as the 2015 political imbroglio increased drug price uncertainty, investors pulled money broadly out of health care.

That defensive position came under attack in 2015 as political rhetoric from both sides zeroed in on perceived unfair drug pricing.

Express Scripts, which in its role as a pharmacy benefit manager negotiates drug prices and reimbursement on behalf of insurers and employers, «will work with health plans and plan sponsors to decide where they want [Luxturna] on their plans,» Miller said.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

As the issue of drug - price gouging became part of the political discussion, the documents show that Turing's board sought advice on how to control the damage and frame a decision to cut the price in some instances.

While some remain defiant and plan to continue their work, one party in particular stands to benefit if the new policy restricts legal sales and pushes prices up — Mexican drug traffickers who see marijuana as a kind of cash crop.

Saunders has openly argued that pharma can head off more stringent drug price regulation in the U.S. (such as Trump's suggestions of competitive bidding and direct negotiations in Medicare) by self - policing.

Although the FDA can't dictate prices or reject therapies over pricing concerns (they can only focus on safety and efficacy), the agency can encourage more competition through moves like this (as well as speedier approval pathways) which could spur drug makers to produce products that ultimately lower costs for patients — a goal cited by FDA Commissioner Scott Gottlieb in announcing the list.

While several of the present CEOs responded optimistically to the meeting — praising the deregulation and tax reduction components in particular — and many of their companies» shares rose on hopes that Trump won't be as antagonistic toward drug makers as his recent comments that they're «getting away with murder» on prices would suggest, don't count on the wish list to come true.

Before, during, and after the trial, Shkreli has cultivated a reputation as America's most hated man, increasing the price of a life - saving drug by 5,000 %, holding an anticipated Wu - Tang album hostage, harassing women on Twitter, and for his smug court appearances.

Generic drug giant Mylan is cutting its financial outlook as it continues to face pressure from falling generic drug prices (a fate that similarly struck rival Teva Pharmaceuticals).

Given its areas of specialization, Gilead wouldn't benefit as much from consolidation as, say, a generic - drug company would, but it still faces pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C drugs, which can cost more than $ 80,000 for a 12 - week course.

Last week, for example, CVS said that prescription drug «hyperinflation» — defined as price increases of more than 100 % and as much as 5,000 % — contributed less than 0.7 % to overall cost growth for its PBM clients.

MÅLOV, Denmark, Nov 21 (Reuters)- Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States.

And despite the fact that Mylan raised EpiPen prices roughly 30 % in 2015 while prescription volume also grew 7 %, the company's revenue on the drug actually fell slightly, as the other players took even bigger cuts, according to Raffat.

MÅLOV, Denmark, Nov 21 - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as its established diabetes drugs come under price pressure, particularly in the United States.

«Drug Pricing companies under scrutiny for prices increases, such as Alexion, would benefit,» Golub wrote.

As well, if the U.S. government takes on the responsibility for buying drugs, it may force better pricing terms on producers, which could hurt revenues.

But she said there also are temporary factors pushing up inflation, such as a rise in prescription drug prices.

As Bresch noted, drug pricing is a complicated issue, and the entire medical sector has a part to play in it.

But as these recent fiery debates within the drug industry underscore, pharma's price hike tactics, now under constant public scrutiny, may well lead to more far - reaching change — whether imposed by legislation or by biopharma companies upon themselves.

That reality would seem to suggest that the U.S. should adopt a system similar to those in other countries, which more tightly regulate drug prices and where the government largely subsidizes health care costs (as opposed to employers largely doing so in the U.S.) through what's known as a single - payer system.

After all, as Regeneron CEO Len Schleifer pointed out, pricing a drug to its value would suggest that its price shouldn't have to be raised year after year, even if it's by the single digits.

By bringing a drug that's been well - established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny — it will also receive a coveted «priority review voucher» which it can hawk to another firm for tens (or even hundreds) of millions of dollars.

I hope so, particularly in light of pharmaceutical companies frequently pointing to the high costs of developing new drugs as being the primary reason prices are so high for existing drugs.

With recent uproar over drug price hikes by Valeant (vrx), Mylan (myl) and Martin Shkreli, healthcare experts have reached a consensus: The system as we know it is officially broken.

And in Europe, biosimilars have driven down the prices of some drug types by as much as 50 %.

JPMorgan health care expert Lisa Gill shared her thoughts on the hotly - followed drug pricing debate as well as potential stock picks.